Cyclo Therapeutics, Inc. (NASDAQ:CYTH) Short Interest Up 32.4% in August

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) saw a significant growth in short interest in the month of August. As of August 31st, there was short interest totalling 200,000 shares, a growth of 32.4% from the August 15th total of 151,100 shares. Based on an average daily trading volume, of 72,500 shares, the short-interest ratio is presently 2.8 days. Approximately 1.2% of the company’s stock are short sold.

Analyst Ratings Changes

Several analysts have issued reports on the stock. HC Wainwright reaffirmed a “neutral” rating and issued a $0.95 price objective (down previously from $3.00) on shares of Cyclo Therapeutics in a research report on Friday, August 23rd. Ascendiant Capital Markets lowered their price target on shares of Cyclo Therapeutics from $2.60 to $0.95 and set a “buy” rating for the company in a report on Monday, August 26th. Finally, Maxim Group reiterated a “hold” rating on shares of Cyclo Therapeutics in a report on Tuesday, August 27th.

Cyclo Therapeutics Stock Performance

NASDAQ CYTH remained flat at $0.64 during mid-day trading on Monday. The company’s stock had a trading volume of 20,663 shares, compared to its average volume of 78,459. Cyclo Therapeutics has a 12-month low of $0.59 and a 12-month high of $2.12. The firm’s fifty day simple moving average is $1.03 and its two-hundred day simple moving average is $1.25. The stock has a market capitalization of $18.37 million, a P/E ratio of -0.64 and a beta of -0.38.

Cyclo Therapeutics (NASDAQ:CYTH) last released its earnings results on Thursday, August 15th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.07). The business had revenue of $0.12 million for the quarter, compared to analysts’ expectations of $0.40 million. Cyclo Therapeutics had a negative net margin of 1,830.27% and a negative return on equity of 2,741.89%. Equities analysts expect that Cyclo Therapeutics will post -0.66 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Cyclo Therapeutics stock. Founders Fund V Management LLC bought a new position in Cyclo Therapeutics, Inc. (NASDAQ:CYTH) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 480,708 shares of the company’s stock, valued at approximately $764,000. Cyclo Therapeutics makes up about 80.8% of Founders Fund V Management LLC’s portfolio, making the stock its biggest position. Founders Fund V Management LLC owned 2.11% of Cyclo Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 68.55% of the company’s stock.

Cyclo Therapeutics Company Profile

Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.